{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Prothrombin Time; decrease to low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Prothrombin Time; To normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Prothrombin Time; increase to high"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"PTT; decrease to low"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"PTT; To normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"PTT; increase to high"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood samples were collected for the assessment of following coagulation parameters: prothrombin time and partial thromboplastin time (PTT). A laboratory value that is outside the normal range is considered either high abnormal (value above the upper limit of the normal range) or low abnormal (value below the lower limit of the normal range). Participants were counted twice if the participant had values in 'Decreased to low' and 'Increased to high' during the post-Baseline period. Data for worst case post Baseline is presented.","groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.","id":"OG000","title":"GSK3377794"},{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.","id":"OG001","title":"GSK3377794+Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Modified ITT Population. Only those participants with data available at the specified time point is reported","reportingStatus":"POSTED","timeFrame":"Up to 108 weeks","title":"Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline","type":"PRIMARY","unitOfMeasure":"Participants"}